SNDL Stock Price: Sundial Growers Inc closes the week flat despite MORE Act passing
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NASDAQ:SNDL was unchanged during Friday’s trading session.
- The MORE Act passes through the House of Representatives on Friday.
- The challenge will still be making its way through the Senate.
NASDAQ:SNDL erased its early session gains once again on Friday, as the positive outcome of the MORE Act was not enough to boost the stock to a positive day. Shares of SNDL traded even and were unchanged on Friday, as shares closed the week down by 8.62%. Wall Street kicked off the second quarter of 2022 in the green as all three major indices closed the session higher. It was a nice start to April, although stock pared their gains by the closing bell. The Dow Jones added 139 basis points, the S&P 500 gained 0.34%, and the NASDAQ climbed by 0.29% during the session.
Stay up to speed with hot stocks' news!
The major news in the cannabis industry on Friday was that the MORE Act vote passed in the House of Representatives. This was somewhat of an expected outcome, especially as the bill received mostly bipartisan support earlier in the week. While most would view this as a positive result, cannabis investors were clearly not as bullish. Most stocks in the sector traded lower during Friday’s session, including industry leaders like Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC), and Aurora Cannabis (NASDAQ:ACB). The sector also posted a loss for the week, despite the news.
SNDL stock forecast
While the vote passing in the House of Representatives is a net positive, the true challenge for the MORE Act will be successfully making its way through the Senate. Investors have been reminded over and over again that this exact situation happened in 2020, where the Senate ultimately struck the bill down. The sentiment on Wall Street is the situation might not be any different this time around.
- NASDAQ:SNDL was unchanged during Friday’s trading session.
- The MORE Act passes through the House of Representatives on Friday.
- The challenge will still be making its way through the Senate.
NASDAQ:SNDL erased its early session gains once again on Friday, as the positive outcome of the MORE Act was not enough to boost the stock to a positive day. Shares of SNDL traded even and were unchanged on Friday, as shares closed the week down by 8.62%. Wall Street kicked off the second quarter of 2022 in the green as all three major indices closed the session higher. It was a nice start to April, although stock pared their gains by the closing bell. The Dow Jones added 139 basis points, the S&P 500 gained 0.34%, and the NASDAQ climbed by 0.29% during the session.
Stay up to speed with hot stocks' news!
The major news in the cannabis industry on Friday was that the MORE Act vote passed in the House of Representatives. This was somewhat of an expected outcome, especially as the bill received mostly bipartisan support earlier in the week. While most would view this as a positive result, cannabis investors were clearly not as bullish. Most stocks in the sector traded lower during Friday’s session, including industry leaders like Tilray (NASDAQ:TLRY), Canopy Growth (NASDAQ:CGC), and Aurora Cannabis (NASDAQ:ACB). The sector also posted a loss for the week, despite the news.
SNDL stock forecast
While the vote passing in the House of Representatives is a net positive, the true challenge for the MORE Act will be successfully making its way through the Senate. Investors have been reminded over and over again that this exact situation happened in 2020, where the Senate ultimately struck the bill down. The sentiment on Wall Street is the situation might not be any different this time around.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.